Léčba AL-amyloidózy - výsledky jednoho pracoviště a přehled publikovaných zkušeností s novými léky (bortezomibem, thalidomidem a lenalidomidem) u AL-amyloidózy
| Title in English | Treatment of AL-amyloidosis-results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis |
|---|---|
| Authors | |
| Year of publication | 2010 |
| Type | Article in Periodical |
| Magazine / Source | Vnitřní lékařství |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | AL-amyloidosis;monoclonal gammopathy; light chain deposition disease; thalidomide; bortezomib; nephortic syndrome |
| Description | 15 patients with light chain deposits in the form of AL-amyloidosis and 2 patients with light chain deposition as amorphous matter (light chain deposition disease) were treated at our clinic as of 1999. Combination of thal, dexamethasone and cyclophosphamide (CTD) was used in 4 patients. Treatment combination of Velcade, cyclophosphamide and dexamethasone (VCD) was used in 3 patients. In one patient (6 completed CTD cycles with the PR result) this combination led to complete haematological remission, complete remission was also achieved in the second patient and the application of 2 CVD cycles led to CR in the third (5 CTD cycles with PR result). Just one of the 3 female patients has been followed up for more than 12 months and so it is possible to evaluate organ treatment response in this patient; nephrotic syndrome ceased, meaning that organ CR has been achieved. Early diagnosis enables administration of aggressive treatment with the outlook of complete haematological and organ treatment response. |
| Related projects: |
|